Version history

{
  "session_id": "fea-6a076c941f7f",
  "round_number": 1,
  "agent_persona": "persona-evidence_auditor",
  "action": "audit_evidence",
  "content": "\n\n**Evidence Audit: Pathway Diagram for GPR109A vs. Microglial-Amyloid-Cytokine Activation Model (v1)**\n\n**Relevance**: Moderate. A GPR109A pathway diagram may show relevant molecular interactions, but the claim involves a complex multi-component model (microglia-amyloid-cytokine). The diagram's direct applicability depends entirely on whether it explicitly depicts these three elements and their mechanistic relationships. Pathway diagrams are inherently schematic—showing possible connections rather than established causal relationships.\n\n**Statistical rigor**: Weak. Pathway diagrams are conceptual illustrations, not data presentations. They contain no effect sizes, confidence intervals, p-values, or quantitative treatment effects. Any purported interactions are hypothetical constructs, not statistically validated findings.\n\n**Sample adequacy**: Not applicable. Pathway diagrams have no sample size considerations. This dimension cannot be assessed and represents a fundamental limitation for evaluating empirical claims.\n\n**Reproducibility indicators**: Weak. Standard pathway diagrams do not include replication data, validation studies, or independent verification of depicted interactions.\n\n**Confounds**: Weak. Pathway diagrams do not address alternative explanations or control for confounding variables. They represent single hypothesized models without comparative or negative controls.\n\n**Key Concerns**:\n- Pathway diagrams lack quantitative data to support model validity\n- No statistical evidence links GPR109A to the claimed microglial-amyloid-cytokine axis\n- Conceptual pathway maps cannot replace experimental validation\n- Sample/replication information absent\n\n**Preliminary Verdict**: Does not support the claim as stated. A pathway diagram provides conceptual illustration but cannot substitute for experimental data demonstrating the Microglial-Amyloid-Cytokine Activation Model's validity.\n\n{\"evidence_score\": 0.15, \"relevance\": \"moderate\", \"statistical_rigor\": \"weak\", \"key_concerns\": [\"Pathway diagrams contain no statistical data (effect sizes, p-values, CIs)\", \"No sample size or replication information provided\", \"Conceptual maps cannot validate complex biological models\", \"No evidence addressing confounds or alternative explanations\"], \"preliminary_verdict\": \"does_not_support\"}"
}